Presentation from the conference Science diplomacy in action Governance for international science co-operation: the example of Health Research 11-12 February, 2013, arranged by the French and British embassies as a follow up to the OECD STIG project, see http://beyondstig.oecd.org
The document discusses the role and responsibilities of Medical Affairs departments within pharmaceutical companies. It describes how Medical Affairs operates medical information functions, provides insights from research to brand teams, cultivates relationships with key opinion leaders, and oversees publication planning and medical writing. Medical Affairs contributes to promotional review and provides market intelligence. The functions of Medical Affairs are organized globally and sometimes by business unit or therapeutic area at the local level. Key areas of specialization within Medical Affairs include medical services, medical research, and medical liaisons.
Global Impact Of Sunshine Act June 7 8 Philadelphia Yavuz Silay MD,MBAYavuz Silay
This document announces a conference to help pharmaceutical and medical device companies comply with the Physician Payments Sunshine Act. The conference will provide information on the new regulations, best practices for data collection and reporting, challenges physicians may face with additional transparency, and how to determine what payments must be reported. It encourages compliance professionals in areas like regulatory affairs, government relations, and marketing to attend in order to accurately report payments and gifts to physicians as required by law.
This document is a short story told from the perspective of a young girl who befriends her elderly neighbor, Miss Ann. The narrator enjoys making up stories and imagining tragic pasts for people like Miss Ann, who lives alone. She visits Miss Ann regularly, though Miss Ann is often rude. When Miss Ann has a stroke and is hospitalized, the narrator visits and discovers Miss Ann has a son who comes to see her. Miss Ann later passes away. The narrator reflects on how her imagined stories did not capture the true loneliness and sadness of Miss Ann's life. Storytelling provides comfort, but real life is often sadder than any story.
Jean-Claude Bradley presents at the Opal Events 3rd Annual Drug Discovery Partnership: Filling the Pipeline on Pre-competitive Collaboration: Sharing Data to Increase Predictability
A presentation I made at a large pharmaceutical industry conference in 2007. Initial speaker (to the 5.5 minute mark) is the chair of the session, Eric Towler. The session was focused on the Evolving Role of Project Management in Drug Development, and my portion was focused on Resource Planning and Management.
For additional context, see related blog post at http://hermosatech.com
At least 400 million people worldwide lack access to essential health services and 2 billion cannot afford the medicines they need. Meanwhile, the global cost of healthcare has jumped to 6.5 trillion US dollars. Access is a huge and complex issue, which affects both developing and developed countries.
Today Carol Lynch, our Global Head of Biopharmaceuticals, gave a keynote address to the European Biosimilars Group highlighting how biosimilars can help transform patient outcomes and calling for all stakeholders to work together to build trust and confidence. You can read the presentation here
Dear all,
I have tried putting down my view-points on benefits of Project Management system in Pharmaceutical Industry...
Please let me know what do you think.
Regards,
Megha Thakkar
The document discusses the role and responsibilities of Medical Affairs departments within pharmaceutical companies. It describes how Medical Affairs operates medical information functions, provides insights from research to brand teams, cultivates relationships with key opinion leaders, and oversees publication planning and medical writing. Medical Affairs contributes to promotional review and provides market intelligence. The functions of Medical Affairs are organized globally and sometimes by business unit or therapeutic area at the local level. Key areas of specialization within Medical Affairs include medical services, medical research, and medical liaisons.
Global Impact Of Sunshine Act June 7 8 Philadelphia Yavuz Silay MD,MBAYavuz Silay
This document announces a conference to help pharmaceutical and medical device companies comply with the Physician Payments Sunshine Act. The conference will provide information on the new regulations, best practices for data collection and reporting, challenges physicians may face with additional transparency, and how to determine what payments must be reported. It encourages compliance professionals in areas like regulatory affairs, government relations, and marketing to attend in order to accurately report payments and gifts to physicians as required by law.
This document is a short story told from the perspective of a young girl who befriends her elderly neighbor, Miss Ann. The narrator enjoys making up stories and imagining tragic pasts for people like Miss Ann, who lives alone. She visits Miss Ann regularly, though Miss Ann is often rude. When Miss Ann has a stroke and is hospitalized, the narrator visits and discovers Miss Ann has a son who comes to see her. Miss Ann later passes away. The narrator reflects on how her imagined stories did not capture the true loneliness and sadness of Miss Ann's life. Storytelling provides comfort, but real life is often sadder than any story.
Jean-Claude Bradley presents at the Opal Events 3rd Annual Drug Discovery Partnership: Filling the Pipeline on Pre-competitive Collaboration: Sharing Data to Increase Predictability
A presentation I made at a large pharmaceutical industry conference in 2007. Initial speaker (to the 5.5 minute mark) is the chair of the session, Eric Towler. The session was focused on the Evolving Role of Project Management in Drug Development, and my portion was focused on Resource Planning and Management.
For additional context, see related blog post at http://hermosatech.com
At least 400 million people worldwide lack access to essential health services and 2 billion cannot afford the medicines they need. Meanwhile, the global cost of healthcare has jumped to 6.5 trillion US dollars. Access is a huge and complex issue, which affects both developing and developed countries.
Today Carol Lynch, our Global Head of Biopharmaceuticals, gave a keynote address to the European Biosimilars Group highlighting how biosimilars can help transform patient outcomes and calling for all stakeholders to work together to build trust and confidence. You can read the presentation here
Dear all,
I have tried putting down my view-points on benefits of Project Management system in Pharmaceutical Industry...
Please let me know what do you think.
Regards,
Megha Thakkar
€5 billion from the EU and European pharmaceutical industry has been committed through the Innovative Medicines Initiative (IMI) public-private partnership to support drug discovery projects. IMI has funded 68 projects through open calls for proposals and established collaborations between academia, small and medium enterprises, large pharmaceutical companies, and regulators. IMI projects have resulted in over 1,100 publications, secured relevance for regulatory guidelines, generated over 2,000 direct jobs and 13,000 indirect jobs, and led to new companies and joint ventures in the biomedical sector.
The document profiles Sabin C. Carme, a transdisciplinary scientist with experience in industry R&D, innovation, and business. It discusses two company cases he has evaluated: PAPE, which involves a drug delivery system using local palladium activation for low toxicity therapy, and opportunities for building strategic advantages. It also includes an analysis of the company's competitive advantage, business model, market forces, strengths, weaknesses and opportunities for further assessment.
The Changing Pharma R&D Model, GDDIS Leaders Summit Ted Torphy CSO, Head, External Innovation Research Excellence, Advance Technologies Janssen R&D
A Johnson & Johnson Pharmaceutical Company
Previous Position
www.gbx.uk.com
www.gddis.com
www.gddif.com
www.wddis.com
The document discusses challenges facing the life sciences industry such as rising development costs, new technologies, and changing expectations. It notes the industry is less innovative and ecosystems are emerging that span activities, geographies, and industries. These ecosystems will be collaborative and open, transcending traditional boundaries. The document proposes a target innovation model for organizations to develop an operating model with a vision for innovation in the new ecosystem landscape.
Reinventing Life Sciences: How emerging ecosystems fuel innovationIBM in Healthcare
Persistent disruptive forces in life sciences now threaten traditional business models over the medium to long term. While high rates of return and strong performance may have masked these forces in the past, today they must be recognized and addressed. Organizations need new ways to continue to thrive despite such hurdles.
This latest research study by IBM Instritute of Business Value in collaboration with the University of California, San Diego and Oxford Economics, led to a target innovation model that can guide organizations to discover operational efficiencies, nurture new growth and get positioned more strategically in the new life sciences and healthcare ecosystem.
MEDICA MEDIA FORUM
„ePatient/Health 2.0: Schlüsselfaktor für neue, zukunftsfähige Geschäftsmodelle der Life Sciences Industrie“
Impulsreferat von Matthias Wartenberg, Executive Director Advisory Service LifeScience, Ernst & Young, Eschborn
This document discusses three main challenges facing the medical technology industry: 1) sustaining innovation given strains on the industry's traditional innovation model, 2) delivering value and health outcomes as payment models shift focus from volume to quality, and 3) fueling growth opportunities in the emerging "health outcomes ecosystem." The medical technology industry faces unprecedented challenges from trends in capital markets, deals, and regulation that threaten key aspects of its business model. Companies will need to adapt their approaches to innovation, value demonstration, and growth strategies.
At the center of smarter life sciencesis an increasingly more networked operation focused on the end patient. The result is also a safe, effective and valued treatment solution targeted at the patient.
The document discusses the need for a new paradigm for funding and conducting biotech research and development (R&D) given constraints in the current financing environment. It proposes a model called Holistic Open Learning Networks (HOLNets) that would bring together diverse participants like healthcare providers, patient groups, data analytics firms, and social media networks. HOLNets could fundamentally change R&D by encouraging data sharing, allowing researchers to learn from each other in real time, and taking advantage of the shift in healthcare to outcomes-focused and data-driven models.
The document discusses the HealthTIES program, an EU-funded initiative to support regional innovation ecosystems in health. It provides context on relevant science and innovation roadmaps and frameworks. The HealthTIES approach involves modeling regional health innovation systems, gathering data on inputs and outputs, benchmarking regions, and developing joint action plans. The program aims to strengthen regions' capacities in life sciences and medical technologies through improved collaboration between research institutions and industry.
The document discusses portfolio management techniques in the pharmaceutical industry. It covers 3 main topics:
1. The changing performance and drivers of the pharmaceutical industry that necessitate sophisticated portfolio management approaches.
2. How companies can shape their portfolio of candidates through comprehensive analysis of opportunities and strategic options to focus on areas of unmet need and core competencies.
3. The basics of marketing company portfolio management, including tools to identify, prioritize, and understand pipeline projects and marketed products to optimally allocate resources.
10th Annual Pricing & Reimbursement (2011) PpPiyush Patel
The document announces the 10th Annual Pricing and Reimbursement Conference taking place on September 14-15, 2011 in London. It will address the latest developments in value-based pricing, the impact of healthcare reform in various countries, and risk-sharing pricing schemes across Europe. Key topics include accessibility to vaccines, pricing and reimbursement in changing healthcare environments, European centralization of health technology assessment, and clinical pathways and audits for pharmaceutical reimbursement. The conference brings together industry leaders from pricing, market access, health economics and related fields.
Jon Bigelow discussed 8 trends in medical communications that matter including: 1) physicians practicing in a 24/7 world, 2) the recession resetting healthcare, 3) pharma restructuring, 4) a focus on specialty markets and emerging nations, 5) a reinvigorated FDA, 6) reforming healthcare through regulation and legislation, 7) increasing pharmaskepticism, and 8) the need for a call to action to address challenges in medical communications. He emphasized the importance of proactively presenting the value and best practices of medical communicators to multiple stakeholders.
Jon Bigelow discussed 8 trends in medical communications that matter including: 1) physicians practicing in a 24/7 world, 2) the recession resetting healthcare, 3) pharma restructuring, 4) a focus on specialty markets and emerging nations, 5) a reinvigorated FDA, 6) reforming healthcare through regulation and legislation, 7) increasing pharmaskepticism, and 8) the need for a call to action to address challenges in medical communications. He emphasized the importance of proactively presenting the value and best practices of medical communicators to multiple stakeholders.
PPP in Research Development and Innovation for the Southern MediterraneanWesley Schwalje
The European Investment Bank used our research as background for its presentation on PPPs in Research Development and Innovation for the Southern Mediterranean region citing our work as the rationale for improved skill creation; increased technology transfer through FDI; employment creation; and enhanced regulatory framework for business.
The post-COVID Value Shift & How MedTech Companies can CapitalizeGreenlight Guru
The ongoing COVID-19 pandemic has fundamentally shifted the perception of value globally. The healthcare industry, and MedTech (Devices, Diagnostics and Digital Health) stand to benefit enormously. While the world waits for a vaccine, it has been MedTech companies and their solutions that have protected healthcare workers, kept patients alive, and been the focus of government policy and investment. The policy and funding shifts have been aligned to value-based healthcare principals, of which MedTech was already a leader. Discover how you can align your organization, and engage with key stakeholders to capitalize on this massive shift in value perception.
Takeaways:
- How the fundamental structure of healthcare is set to change
-How this fundamental change will benefit MedTech companies
-What you need to do in order to make this change sustainable within your organization
This session took place live at the Greenlight Guru True Quality Virtual Summit, a three-day event for medical device professionals to learn to get their devices to market faster, stay ahead of regulatory changes, and use quality as their multiplier to grow their device business.
How AI and Machine Learning can improve patient access to orphan drugs.pptxVidyaBreeveldDwarkas
On March 22 2022 I held this thought provoking presentation about the use of modern information technologies to aid patient access to orphan drugs at the World EPA congress in Amsterdam.
My conclusion: These technologies could be valuable instruments that help to provide solutions to fill the data gaps in health technology assessments and guide policy decisions. However, since there are many actors involved, to improve patient access to orphan drugs an ecosystem innovation is needed. Unless this is addressed, these modern technologies will not provide solutions that benefit patient access.
Hvordan kan fremtidsferdigheter bidra til en utfordringsorientert politikk?Per Koch
Dette er grunnen til at vi må bli bevisst vår egen bruk av fremtiden om vi skal utvikle policy-tiltak som svarer på fremtidens behov. En kort presentasjon av Futures Literacy eller fremtidsferdigheter.
Forskningens rolle i skeiv historie, undertrykker eller frigjører?Per Koch
Forskningens behandling av homofile og transkjønnede kan tjene som et godt eksempel på hvordan forskere ikke opererer i et kulturellt vakum, men faktisk er en del av samfunnet, og ofte deler samfunnets fordommer.
Forskningsmiljøene utvikler teorier, metoder og former for praksis som invaliderer og utestenger marginaliserte grupper, basert på forestillinger som anses som "selvfølgelige" i deres kulturelle omkrets.
Pyskiatriens sykeliggjøring av skeive fra 1800-tallet og fremover bidro til forfølgelsen av folk med en seksuell orientering eller kjønnsidentitet som avviker fra cis/hetero-normen.
Homfobe og transfobe aktivister bruker forskning aktivt i sin undertrykkelse, og om de ikke finner forskning som passer dem vil de presentere det de finner på en måte som synes å bekrefte dere forestillinger. Dette er et moralsk, kulturelt og politisk problem.
Denne presentasjonen drøfter ulike paradigmer i psykatrien, hvordan de er blitt til i et samspill mellom forskere og skeive folk og hvordan "friskmeldingen" av skeive folk var like mye et resultat av kulturell og politisk utvikling som vitenskapsinterne prosesser.
Presentasjonen ser også på hvordan det ekstreme venstre (TERFer) og det ekstreme høyre har utviklet en felles narrativ som brukes for å undertrykke transfolk.
Ideen om at forskere skal ha makt til å definere folks identitet og rett til respekt og anerkjennelse må forlates. Dette er etiske, politiske og kulurelle spørsmål, ikke noe som kan delegeres til medisinen.
More Related Content
Similar to Boosting drug development through public private partnerships (Laverty OECD Paris Feb 2013)
€5 billion from the EU and European pharmaceutical industry has been committed through the Innovative Medicines Initiative (IMI) public-private partnership to support drug discovery projects. IMI has funded 68 projects through open calls for proposals and established collaborations between academia, small and medium enterprises, large pharmaceutical companies, and regulators. IMI projects have resulted in over 1,100 publications, secured relevance for regulatory guidelines, generated over 2,000 direct jobs and 13,000 indirect jobs, and led to new companies and joint ventures in the biomedical sector.
The document profiles Sabin C. Carme, a transdisciplinary scientist with experience in industry R&D, innovation, and business. It discusses two company cases he has evaluated: PAPE, which involves a drug delivery system using local palladium activation for low toxicity therapy, and opportunities for building strategic advantages. It also includes an analysis of the company's competitive advantage, business model, market forces, strengths, weaknesses and opportunities for further assessment.
The Changing Pharma R&D Model, GDDIS Leaders Summit Ted Torphy CSO, Head, External Innovation Research Excellence, Advance Technologies Janssen R&D
A Johnson & Johnson Pharmaceutical Company
Previous Position
www.gbx.uk.com
www.gddis.com
www.gddif.com
www.wddis.com
The document discusses challenges facing the life sciences industry such as rising development costs, new technologies, and changing expectations. It notes the industry is less innovative and ecosystems are emerging that span activities, geographies, and industries. These ecosystems will be collaborative and open, transcending traditional boundaries. The document proposes a target innovation model for organizations to develop an operating model with a vision for innovation in the new ecosystem landscape.
Reinventing Life Sciences: How emerging ecosystems fuel innovationIBM in Healthcare
Persistent disruptive forces in life sciences now threaten traditional business models over the medium to long term. While high rates of return and strong performance may have masked these forces in the past, today they must be recognized and addressed. Organizations need new ways to continue to thrive despite such hurdles.
This latest research study by IBM Instritute of Business Value in collaboration with the University of California, San Diego and Oxford Economics, led to a target innovation model that can guide organizations to discover operational efficiencies, nurture new growth and get positioned more strategically in the new life sciences and healthcare ecosystem.
MEDICA MEDIA FORUM
„ePatient/Health 2.0: Schlüsselfaktor für neue, zukunftsfähige Geschäftsmodelle der Life Sciences Industrie“
Impulsreferat von Matthias Wartenberg, Executive Director Advisory Service LifeScience, Ernst & Young, Eschborn
This document discusses three main challenges facing the medical technology industry: 1) sustaining innovation given strains on the industry's traditional innovation model, 2) delivering value and health outcomes as payment models shift focus from volume to quality, and 3) fueling growth opportunities in the emerging "health outcomes ecosystem." The medical technology industry faces unprecedented challenges from trends in capital markets, deals, and regulation that threaten key aspects of its business model. Companies will need to adapt their approaches to innovation, value demonstration, and growth strategies.
At the center of smarter life sciencesis an increasingly more networked operation focused on the end patient. The result is also a safe, effective and valued treatment solution targeted at the patient.
The document discusses the need for a new paradigm for funding and conducting biotech research and development (R&D) given constraints in the current financing environment. It proposes a model called Holistic Open Learning Networks (HOLNets) that would bring together diverse participants like healthcare providers, patient groups, data analytics firms, and social media networks. HOLNets could fundamentally change R&D by encouraging data sharing, allowing researchers to learn from each other in real time, and taking advantage of the shift in healthcare to outcomes-focused and data-driven models.
The document discusses the HealthTIES program, an EU-funded initiative to support regional innovation ecosystems in health. It provides context on relevant science and innovation roadmaps and frameworks. The HealthTIES approach involves modeling regional health innovation systems, gathering data on inputs and outputs, benchmarking regions, and developing joint action plans. The program aims to strengthen regions' capacities in life sciences and medical technologies through improved collaboration between research institutions and industry.
The document discusses portfolio management techniques in the pharmaceutical industry. It covers 3 main topics:
1. The changing performance and drivers of the pharmaceutical industry that necessitate sophisticated portfolio management approaches.
2. How companies can shape their portfolio of candidates through comprehensive analysis of opportunities and strategic options to focus on areas of unmet need and core competencies.
3. The basics of marketing company portfolio management, including tools to identify, prioritize, and understand pipeline projects and marketed products to optimally allocate resources.
10th Annual Pricing & Reimbursement (2011) PpPiyush Patel
The document announces the 10th Annual Pricing and Reimbursement Conference taking place on September 14-15, 2011 in London. It will address the latest developments in value-based pricing, the impact of healthcare reform in various countries, and risk-sharing pricing schemes across Europe. Key topics include accessibility to vaccines, pricing and reimbursement in changing healthcare environments, European centralization of health technology assessment, and clinical pathways and audits for pharmaceutical reimbursement. The conference brings together industry leaders from pricing, market access, health economics and related fields.
Jon Bigelow discussed 8 trends in medical communications that matter including: 1) physicians practicing in a 24/7 world, 2) the recession resetting healthcare, 3) pharma restructuring, 4) a focus on specialty markets and emerging nations, 5) a reinvigorated FDA, 6) reforming healthcare through regulation and legislation, 7) increasing pharmaskepticism, and 8) the need for a call to action to address challenges in medical communications. He emphasized the importance of proactively presenting the value and best practices of medical communicators to multiple stakeholders.
Jon Bigelow discussed 8 trends in medical communications that matter including: 1) physicians practicing in a 24/7 world, 2) the recession resetting healthcare, 3) pharma restructuring, 4) a focus on specialty markets and emerging nations, 5) a reinvigorated FDA, 6) reforming healthcare through regulation and legislation, 7) increasing pharmaskepticism, and 8) the need for a call to action to address challenges in medical communications. He emphasized the importance of proactively presenting the value and best practices of medical communicators to multiple stakeholders.
PPP in Research Development and Innovation for the Southern MediterraneanWesley Schwalje
The European Investment Bank used our research as background for its presentation on PPPs in Research Development and Innovation for the Southern Mediterranean region citing our work as the rationale for improved skill creation; increased technology transfer through FDI; employment creation; and enhanced regulatory framework for business.
The post-COVID Value Shift & How MedTech Companies can CapitalizeGreenlight Guru
The ongoing COVID-19 pandemic has fundamentally shifted the perception of value globally. The healthcare industry, and MedTech (Devices, Diagnostics and Digital Health) stand to benefit enormously. While the world waits for a vaccine, it has been MedTech companies and their solutions that have protected healthcare workers, kept patients alive, and been the focus of government policy and investment. The policy and funding shifts have been aligned to value-based healthcare principals, of which MedTech was already a leader. Discover how you can align your organization, and engage with key stakeholders to capitalize on this massive shift in value perception.
Takeaways:
- How the fundamental structure of healthcare is set to change
-How this fundamental change will benefit MedTech companies
-What you need to do in order to make this change sustainable within your organization
This session took place live at the Greenlight Guru True Quality Virtual Summit, a three-day event for medical device professionals to learn to get their devices to market faster, stay ahead of regulatory changes, and use quality as their multiplier to grow their device business.
How AI and Machine Learning can improve patient access to orphan drugs.pptxVidyaBreeveldDwarkas
On March 22 2022 I held this thought provoking presentation about the use of modern information technologies to aid patient access to orphan drugs at the World EPA congress in Amsterdam.
My conclusion: These technologies could be valuable instruments that help to provide solutions to fill the data gaps in health technology assessments and guide policy decisions. However, since there are many actors involved, to improve patient access to orphan drugs an ecosystem innovation is needed. Unless this is addressed, these modern technologies will not provide solutions that benefit patient access.
Similar to Boosting drug development through public private partnerships (Laverty OECD Paris Feb 2013) (20)
Hvordan kan fremtidsferdigheter bidra til en utfordringsorientert politikk?Per Koch
Dette er grunnen til at vi må bli bevisst vår egen bruk av fremtiden om vi skal utvikle policy-tiltak som svarer på fremtidens behov. En kort presentasjon av Futures Literacy eller fremtidsferdigheter.
Forskningens rolle i skeiv historie, undertrykker eller frigjører?Per Koch
Forskningens behandling av homofile og transkjønnede kan tjene som et godt eksempel på hvordan forskere ikke opererer i et kulturellt vakum, men faktisk er en del av samfunnet, og ofte deler samfunnets fordommer.
Forskningsmiljøene utvikler teorier, metoder og former for praksis som invaliderer og utestenger marginaliserte grupper, basert på forestillinger som anses som "selvfølgelige" i deres kulturelle omkrets.
Pyskiatriens sykeliggjøring av skeive fra 1800-tallet og fremover bidro til forfølgelsen av folk med en seksuell orientering eller kjønnsidentitet som avviker fra cis/hetero-normen.
Homfobe og transfobe aktivister bruker forskning aktivt i sin undertrykkelse, og om de ikke finner forskning som passer dem vil de presentere det de finner på en måte som synes å bekrefte dere forestillinger. Dette er et moralsk, kulturelt og politisk problem.
Denne presentasjonen drøfter ulike paradigmer i psykatrien, hvordan de er blitt til i et samspill mellom forskere og skeive folk og hvordan "friskmeldingen" av skeive folk var like mye et resultat av kulturell og politisk utvikling som vitenskapsinterne prosesser.
Presentasjonen ser også på hvordan det ekstreme venstre (TERFer) og det ekstreme høyre har utviklet en felles narrativ som brukes for å undertrykke transfolk.
Ideen om at forskere skal ha makt til å definere folks identitet og rett til respekt og anerkjennelse må forlates. Dette er etiske, politiske og kulurelle spørsmål, ikke noe som kan delegeres til medisinen.
Why is futures literacy relevant for innovation and innovation policy?Per Koch
This presentation was made at the launch of the new Norwegian UNESCO chair in futures literacy, which is to look at the way the future can be used in leadership and innovation policy learning and development. Previous generations of innovation policy har seen the future as an improved version of the present. It is not problematized. A long series of unexpected crises (climate, pollution, corona, Fascism, Ukraine etc.) has shown us that the future is not given, and that our ideas of the future might actually create a kind of mental lock-in that makes use incapable of handling the crises and challenges when they arrive. By looking at futures literacy and anticipation policy-makers and stakeholders may become more aware of their own mental maps and preconceptions and become more capable of handling societal challenges, complexity and the unexpected.
Tredje generasjons innovasjonspolitikk og målrettede samfunnsoppdrag (mission)Per Koch
En tredjegenerasjons innovasjonspolitikk er rettet mot store samfunnsutfordringer og krever politiske virkemidler som gå på tvers av sektorer. Missions, eller målrettede samfunnsoppdrag, er vertkøy som er ment å kunne brukes i en verden der fremtiden er usikker og utfordringene store. Samfunnsoppdragene har som mål å sikre omstilling i samfunns- og næringsliv som bidrar til løsninger på problemene. Overordnede samfunnsoppdrag skal bidra til omstilling av store deler av samfunnet. Avgrensede samfunnsoppdrag dekker mer begrensede innsatser. Denne presentasjonen presenterer også forskjellen på første generasjons innovasjonspolitikk (den lineære modellen), andre generasjons innovasjonspolitikk (nasjonale innovasjonssystemer) og den nye transformerende innovasjonspolitikken.
Mirza WHO presentation on science diplomacy meeting in Paris 2013, on global ...Per Koch
Presentation from the conference Science diplomacy in action Governance for international science co-operation: the example of Health Research 11-12 February, 2013, arranged by the French and British embassies as a follow up to the OECD STIG project, see http://beyondstig.oecd.org
Presentation from the conference Science diplomacy in action Governance for international science co-operation: the example of Health Research 11-12 February, 2013, arranged by the French and British embassies as a follow up to the OECD STIG project, see http://beyondstig.oecd.org
OECD STIG: Governance of International Science, Technology and Innovation for...Per Koch
This document summarizes the key recommendations from a report on governance of international cooperation on science, technology, and innovation for global challenges. It recommends: 1) taking a broad, multidisciplinary approach that addresses social and cultural factors, not just technologies; 2) exploiting economies of scale and scope through specialized yet complementary cooperation; and 3) allowing diversity and flexibility while respecting each partner's needs. Effective governance requires high-level coordination, communication strategies, aligning agendas with national priorities, legitimizing national funding contributions, and building international capacity.
Presentation of the OECD project on governance of STI for global challengesPer Koch
Presentation given at the ICSU Rio +20 conference in June 2012 on the OECD-project STIG (on international governance collaboration on science, technology and innovation for meeting global challenges.
OECD STIG: Governance of international research and innovation cooperation fo...Per Koch
Presentation of the OECD STIG-project on governance of international science, technology and innovation collaboration for global challenges. OECD STIG October 2011. Chair's presentation. UPDATE Nov 7 2012: Vi have set up a new blog on the follow up of STIG over at http://beyondstig.blogspot.com
Presentation on policy learning and science, technology and innovation policy governance. Originally presented for the Gordon Conference on Science Policy in 2010.
Presentation originally made for the Gordon Conference on Science Policy 2010. On policy learning and innovation in science, technology and innovation policy governance.
Koch taftie-measuring the effects of researchPer Koch
1. Evaluating the effects of research and innovation investments on a national level is challenging due to the complexity of social systems and interaction of many factors.
2. Traditional linear models of innovation are limited and a systemic perspective is needed to understand how research contributes to economic and social outcomes through competence flows and learning.
3. Both quantitative and qualitative methods must be combined to measure direct and indirect outcomes of policies and understand the context in which innovation occurs.
User data collected by search engines and other online services provides benefits but also risks to user privacy. As data storage and processing capabilities increase, more user information can be aggregated and analyzed from various sources. This raises concerns about potential misuse of personal data by authorities, companies, and other entities. To build trust, search engines must implement strong privacy policies and transparency around data practices. An independent international organization may help set standards to balance innovation with privacy protection.
The document discusses innovation in the public sector based on findings from the PUBLIN project. It defines innovation as new practices, processes, products, or organizational relationships introduced with a specific objective in mind. The document outlines types and drivers of innovation, as well as common barriers such as risk aversion, professional resistance, and lack of resources. It provides recommendations to promote innovation through learning and networking, entrepreneurship, combating institutional barriers, stakeholder engagement, and developing a holistic innovation policy.
Boosting drug development through public private partnerships (Laverty OECD Paris Feb 2013)
1. Boosting drug development through Public-
Private Partnerships: The IMI Model
Hugh Laverty
Senior Scientific Project Manager
Science Diplomacy in Action - Paris Feb 2013
2. The Challenges
Difficulties reaching international agreement on common
priorities
Insufficient modalities of funding
Obstacles to the transfer of science, technology and
innovation into practice
Insufficient participation of relevant actors in society
The lack of integration of countries with weak scientific
infrastructure
Problems of intellectual property mangement for
applications of new technologies
3. The role of Public-Private Partnerships in
driving international science co-operation
PPPs originated in areas focusing on neglected or orphan
diseases, or helping poorer countries
The approach to PPPs has evolved and the model is being
applied to other areas e.g., chronic diseases, and more
mature economies
The emergence of PPPs has been helped by a convergence
of different pressures such as societal, health care and
economic
4. Challenges for society and industry
Society Industry
• Healthcare challenges • Costs for developing new drugs
continue to raise around the continue to increase
world
• Pharma incentive systems and
profitability are under pressure
• A lot of these challenges are
not addressed • We are pushing towards
Personalized Medicine but in
• Pressure on healthcare general, progress in basic science
systems and budgets continue is not translated to medical
to rise innovation and benefits to
patients
5. Innovative Medicines Initiative
The European Union and the
pharmaceutical industry
have joined forces to make
drug R&D processes in Europe more
innovative and efficient
and enhance Europe’s
competitiveness in the sector
& address key societal challenges
by forming
the biggest PPP in Life Science
9. Antibiotic drug development:
‘New Drugs 4 Bad Bugs’
Challenges of AB R&D:
• Unique scientific
bottlenecks
• Challenging
regulatory
environment
• Low return on
investment
Challenges too great for any single entity to solve,
collaboration is essential
10. Antibiotic drug development:
Major challenges
Scientific challenge: screening approaches often fail,
difficult to obtain needed spectrum & safety—challenge
increased for Gram-negative pathogens due to inherent
penetration barriers
Regulatory challenge: large trials needed, non-
inferiority designs, etc.
Economic challenge: (low Return on Investment) ABs
expensive to develop, often give cure in days, new ABs
will be used only when truly needed
11. European Lead Factory
Joint European Compound Library
Joint European Compound Library
accessible for private and public
lead discovery projects
JECL is comprised of a Pharma
Consortium Collection (≥ 300.000
compounds) and a Public Collection
(up to 200.000 cpds.)
The Screening Centre – as an
independent novel business
entity – takes responsibility for
cpd. logistics, HTS (internal and
out-sourced), data analysis &
handling, and project mgtm.
Screening Centre functions as a
market place to broker public-private
discovery projects with the Pharma Consortium
12. How IMI makes a difference
Fosters large scale industry collaboration and engagement
with scientific community
Promotes active involvement of patients, regulators and
payers
Enables innovation via join effort where singular
approach has failed so far
Facilitates Intellectual Property agreements
13. One IMI IP policy, multiple interests
Direct exploitation rights
(academia /SME) Facilitating Fair and reasonable terms
Terms known at outset access for Research Use purposes
(Pharma) for third parties
Dissemination
Incentive to of information
participate
Dissemination
Innovative Medicines within a year
Support for Compensation
EU for IP
Industry
Terms accommodate the needs of
Only necessary background included
a spectrum of interests - large and
Compensation within fair and reasonable
small
terms
14. The Evolution of IMI
From bottlenecks in industry to bottlenecks in society
From push to pull – business & HC impact
+ Drive Regulatory Change
What: translate science into regulatory
Need for a neutral platform
pathways: real life data
How: Collaborate with regulators and payers
Since 2012
+ Facilitate ‘pull’ incentives
What: Reconcile research and health care agendas
How: Engage with regulators and payers
Since 2011
Reduce Attrition and Time to Market
What: Decrease risk by developing improved tools and methodologies, secure
sustainability of outputs
How: Large scale industry collaboration and engagement with scientific community
Since 2008
R&D cycle: From inventive to innovative steps
15. The Challenges
Difficulties reaching international agreement on common
priorities
Insufficient modalities of funding
Obstacles to the transfer of science, technology and
innovation into practice
Insufficient participation of relevant actors in society
The lack of integration of countries with weak scientific
infrastructure
Problems of intellectual property mangement for
applications of new technologies
16. The Challenges
Difficulties reaching international agreement on common
priorities
Insufficient modalities of funding
Obstacles to the transfer of science, technology and
innovation into practice
Insufficient participation of relevant actors in society
The lack of integration of countries with weak scientific
infrastructure
Problems of intellectual property management for
applications of new technologies
17. Ensuring success from future global
initiatives
Mechanisms to allow individuals and institutions
to engage internationally
Inclusive and flexible approach
Clearly defined IPR Policy
Focus on addressing societal needs
Neutral broker